吡格列酮联用二甲双胍治疗2型糖尿病的疗效及安全性分析

目的:评价吡格列酮联用二甲双胍治疗2型糖尿病的临床疗效及安全性。方法:将102例2型糖尿病患者随机分为2组,治疗组采用吡格列酮联用二甲双胍治疗,对照组单用二甲双胍治疗,比较2组血糖和胰岛素指标的变化。结果:连用6个月后2组空腹血糖(FPG)、餐后2h血糖(P2hBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、餐后2h胰岛素(P2hINS)、稳态胰岛素评价指数(HOMA-IR)水平均明显降低,与治疗前比较差异均有统计学意义(P<0.05);但治疗组治疗后FPG、P2hBG、HbA1c、FINS、P2hINS、HOMA-IR水平明显低于同期对照组水平,2组比较差异有统计学意义(P<0.05);2组不良反应少,均未见严重不良反应。结论:吡格列酮联用二甲双胍治疗2型糖尿病,能够明显降低血糖水平,改善胰岛素状态,且不良反应少。

Analysis on Clinical Efficacy and Safety of Pioglitazone Combined with Metformin in the Treatment of Type 2 Diabetes

OBJECTIVE：To analyze clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes.METHODS：102 patients with type 2 diabetes were randomly divided into 2 groups.Treatment group received pioglitazone combined with metformin and treatment group received metformin alone.The levels of blood glucose and insulin were observed and compared between 2 groups.RESULTS：After 6 months of treatment,fasting plasma glucose（FPG）,postprandial 2 h blood glucose（P2hBG）,glycosylated hemoglobin（HbA1c）,fasting insulin（FINS）,postprandial 2 h insulin（P2hINS）,steady-state assessment index of insulin（HOMA-IR） in 2 groups were significantly decreased,there was statistical significance in difference before and after treatment（P0.05）.After treatment,the level of FPG,P2hBG,HbA1c,FINS,P2hINS and HOMA-IR in treatment group was significantly lower than in control group,there was statistical significance（P0.05）;There were few adverse drug reactions,and no serious adverse drug reaction was observed.CONCLUSION：Pioglitazone combined with metformin can significantly lower the level of blood sugar and improve insulin index in patients with type 2 diabetes with few adverse drug reactions.